Home Cart Sign in  
Chemical Structure| 1015474-32-4 Chemical Structure| 1015474-32-4

Structure of Avadomide
CAS No.: 1015474-32-4

Chemical Structure| 1015474-32-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

CC-122, also known as avadomide, binds to CRBN and induces degradation of aiolos and ikaros that result in cell apoptosis. It is a antitumor and immunomodulatory agent used to treat DLBCL.

Synonyms: CC-122; CC 122

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Avadomide

CAS No. :1015474-32-4
Formula : C14H14N4O3
M.W : 286.29
SMILES Code : O=C(C(N1C(C)=NC2=C(C(N)=CC=C2)C1=O)CC3)NC3=O
Synonyms :
CC-122; CC 122
MDL No. :MFCD29919294
InChI Key :RSNPAKAFCAAMBH-UHFFFAOYSA-N
Pubchem ID :24967599

Safety of Avadomide

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • CRBN

In Vitro:

Cell Line
Concentration Treated Time Description References
Hep3B cells 1 μmol/L or 10 μmol/L 12 or 24 hours BMP9 promotes cell cycle progression by reducing RNA m6A methylation levels PMC8133393
DLBCL cell lines (TMD8, U2932, WSU-DLCL2, SUDHL-4) 0.1–10 μmol/L 24 hours To assess the effect of Avadomide on the degradation of Aiolos and Ikaros and the expression of ISGs (e.g., IRF7), results showed that Avadomide significantly increased IRF7 protein expression in sensitive cells. PMC9662945
DLBCL cell lines (TMD8, U2932, WSU-DLCL2, SUDHL-4) 0.1–10 μmol/L 7 days To assess the effect of Avadomide on the degradation of Aiolos and Ikaros and the expression of ISGs (e.g., IRF7), results showed that Avadomide significantly increased IRF7 protein expression in sensitive cells. PMC9662945

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c mice ZMYM2–FGFR1-transformed Ba/F3 leukemia model Oral gavage 50 mg/kg Twice daily for 7 days To evaluate the in vivo antiproliferative effect of avadomide on ZMYM2–FGFR1-dependent leukemia cells, showing significant reduction in tumor burden PMC8133393

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02509039 Lymphoma, Non-Hodgkin PHASE1 TERMINATED 2023-05-09 Local Institution - 002, Koto-... More >>ku, Tokyo, 1358550, Japan|Local Institution - 003, Chikusa-ku, 464-8681, Japan|Local Institution - 001, Kashiwa, 277-8577, Japan Less <<
NCT02234999 Healthy Volunteers PHASE1 COMPLETED 2014-10-08 Covance Clinical Research Unit... More >> Inc, Madison, Wisconsin, 53704, United States Less <<
NCT03097016 Renal Insufficiency PHASE1 COMPLETED 2017-12-23 DaVita Clinical Research, Lake... More >>wood, Colorado, 80228, United States|DaVita Clinical Research, Minneapolis, Minnesota, 55404, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.49mL

0.70mL

0.35mL

17.46mL

3.49mL

1.75mL

34.93mL

6.99mL

3.49mL

References

 

Historical Records

Categories